Mayne Pharma Group Limited (ASX:MYX)

Mayne Pharma Group Company Description

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.

It operates through three segments: Women’s Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers.

It also distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.

The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010.

Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Mayne Pharma Group Limited

Country	Australia
Founded	2005
Industry	Medical Distribution
Sector	Healthcare
Employees	491
CEO	Shawn O’Brien

Contact Details

Address: 1538 Main North Road Salisbury South, SA 5106 Australia
Phone	61 8 8209 2666
Website	maynepharma.com

Stock Details

Ticker Symbol	MYX
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU000000MYX0
SIC Code	2834

Key Executives

Name	Position
Shawn Patrick O'Brien M.B.A., M.S.	Chief Executive Officer, MD and Director
Aaron Gray	Chief Financial Officer
Dr. Thomas Duthy M.B.A., Ph.D.	Manager of Investor Relations
Kimberly Parker J.D.	Executive Vice President and General Counsel
Brant Schofield	Executive Vice President of Corporate Development
Kurt Reyes	Interim Global Head of People
Daniel Moore	Executive Vice President of Specialty Products and Patient Solutions
Dr. Frank Casty M.D.	Executive Vice President, Global Head of Research & Development and Chief Medical Officer
Tony Ramy	Executive Vice President of Women's Health
Brenton Walter	Financial Controller